European Reference Network (ERN) ReCONNET methodology for the cross-cultural adaptation of instruments for research and care in the context of rare connective tissue diseases (CROSSADAPT).

IF 3.4 2区 医学 Q2 GENETICS & HEREDITY
Laurent Arnaud, Oliver Sander, Simona Rednic, Philippe Mertz, Raquel Faria, Francesca Crisafulli, Sofia Silva-Ribeiro, Lou Kawka, Cedric Sztejkowski, Christina Düsing, Thomas Rose, Antonio Lamas, Carlos Vasconcelos, Giulia Fontana, Paolo Semeraro, Teodora Neagu, Mihaela Resteu, Laura Damian, Cristina Pamfil, Camelia Bucsa, Lisa J Matthews, Rosaria Talarico, Marta Mosca, Giuseppe Turchetti, Thomas Thibault, Hervé Devilliers
{"title":"European Reference Network (ERN) ReCONNET methodology for the cross-cultural adaptation of instruments for research and care in the context of rare connective tissue diseases (CROSSADAPT).","authors":"Laurent Arnaud, Oliver Sander, Simona Rednic, Philippe Mertz, Raquel Faria, Francesca Crisafulli, Sofia Silva-Ribeiro, Lou Kawka, Cedric Sztejkowski, Christina Düsing, Thomas Rose, Antonio Lamas, Carlos Vasconcelos, Giulia Fontana, Paolo Semeraro, Teodora Neagu, Mihaela Resteu, Laura Damian, Cristina Pamfil, Camelia Bucsa, Lisa J Matthews, Rosaria Talarico, Marta Mosca, Giuseppe Turchetti, Thomas Thibault, Hervé Devilliers","doi":"10.1186/s13023-025-03674-8","DOIUrl":null,"url":null,"abstract":"<p><p>The traditional process of intercultural adaptation, while suitable for one or a few target languages, is not optimal for developing instruments for rare connective tissue diseases (CTDs) in multiple languages simultaneously. The European Reference Network ReCONNET presents the protocol for a novel methodology for cross-cultural adaptation of instruments for research and care in the context of rare CTDs (ReCONNET-CROSSADAPT). It is initiated by the identification of 'key-terms' that are crucial for maintaining the original meaning of the source document. Each language group, led by a senior member and two collaborators, independently assesses the existence and equivalence of these key terms in target languages. Reconciliation meetings are held to establish agreed-upon terms for consistent usage across translations when difficulties arise with key-terms. Subsequently, each language group translates the source document, followed by a reconciliation meeting involving one CTD patient in each group. The purpose of this meeting is to address potential discrepancies among translations, ensuring a comprehensive assessment from a linguistic, cultural and patient perspective. Collective feedback and consensus-based decision-making guide the resolution process. This methodology eliminates the need for backward translation, optimizing time and cost utilization. This new ReCONNET-CROSSADAPT methodology ensures linguistic accuracy, cultural relevance, and contextual appropriateness for the cross-cultural adaptation of instruments for research and care in the context of rare CTDs.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":"20 1","pages":"230"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080175/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-025-03674-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

The traditional process of intercultural adaptation, while suitable for one or a few target languages, is not optimal for developing instruments for rare connective tissue diseases (CTDs) in multiple languages simultaneously. The European Reference Network ReCONNET presents the protocol for a novel methodology for cross-cultural adaptation of instruments for research and care in the context of rare CTDs (ReCONNET-CROSSADAPT). It is initiated by the identification of 'key-terms' that are crucial for maintaining the original meaning of the source document. Each language group, led by a senior member and two collaborators, independently assesses the existence and equivalence of these key terms in target languages. Reconciliation meetings are held to establish agreed-upon terms for consistent usage across translations when difficulties arise with key-terms. Subsequently, each language group translates the source document, followed by a reconciliation meeting involving one CTD patient in each group. The purpose of this meeting is to address potential discrepancies among translations, ensuring a comprehensive assessment from a linguistic, cultural and patient perspective. Collective feedback and consensus-based decision-making guide the resolution process. This methodology eliminates the need for backward translation, optimizing time and cost utilization. This new ReCONNET-CROSSADAPT methodology ensures linguistic accuracy, cultural relevance, and contextual appropriateness for the cross-cultural adaptation of instruments for research and care in the context of rare CTDs.

欧洲参考网络(ERN)用于罕见结缔组织疾病研究和护理工具的跨文化适应的reconet方法(CROSSADAPT)。
传统的跨文化适应过程虽然适用于一种或几种目标语言,但对于同时使用多种语言开发罕见结缔组织疾病(CTDs)的仪器来说,并不理想。欧洲参考网络ReCONNET提出了一种新的方法,用于在罕见CTDs的背景下研究和护理的跨文化适应工具(ReCONNET- crossadapt)。它是由“关键术语”的识别发起的,这些术语对于保持源文档的原始含义至关重要。每个语言小组由一名高级成员和两名合作者领导,独立评估这些关键术语在目标语言中的存在性和等价性。召开协调会议是为了在关键术语出现困难时建立一致的术语,以便在不同的翻译中使用一致的术语。随后,每个语言组翻译源文件,随后召开调解会议,每组有一名CTD患者参加。本次会议的目的是解决翻译之间潜在的差异,确保从语言,文化和患者的角度进行全面评估。集体反馈和基于共识的决策指导了决议过程。这种方法消除了向后翻译的需要,优化了时间和成本的利用。这种新的ReCONNET-CROSSADAPT方法确保了语言准确性、文化相关性和上下文适切性,以便在罕见CTDs的背景下对研究和护理工具进行跨文化适应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信